Options for Stage III Melanoma

June 2024 Update:

With the recent publication of the NADINA trial on the benefits of neoadjuvant vs adjuvant therapy, the decision-making process for adjuvant therapy in Stage III melanoma is changing. Stay tuned for updates to this content.

Welcome to this pamphlet, Options for Stage III Melanoma: Making the Decision That’s Right for You.  You can use this pamphlet to discuss options for managing Stage III melanoma with your patients. It provides an in-depth discussion of high-risk melanoma, substages of stage III disease, and adjuvant therapy options vs active surveillance. This pamphlet was produced through a collaboration of AIM at Melanoma Foundation and Terranova Medica, LLC. Faculty oversight was provided by

  • Eric D. Whitman, MD, FACS; Medical Director of Atlantic Health System’s Oncology Service Line; Morristown, New Jersey
  • Janice M. Mehnert, MD; Regional Phase 1 Clinical Program Director; Medical Oncologist; Rutgers Cancer Institute; New Brunswick, New Jersey
  • Lisa A. Kottschade, APRN, MSN, CNP; Coordinator, Outpatient Oncology Melanoma Practice; Mayo Clinic; Rochester, Minnesota

The development of this pamphlet was supported by unrestricted educational grants from Bristol Myers Squibb; Merck & Co., Inc; and Novartis Pharmaceuticals Corporation.

We hope you find this pamphlet helpful in supporting shared decision-making for your patients with Stage III melanoma.